{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:29:50Z","timestamp":1793860190485,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11716-x","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:25:55Z","timestamp":1788006355000},"page":"10837-10852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing machine learning, docking and molecular dynamics for the virtual screening of compounds as CDK4\/6 dual inhibitors"],"prefix":"10.1007","volume":"30","author":[{"given":"Yuxi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"1","key":"11716_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tcb.2021.07.001","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu J, Peng Y, Wei W (2022) Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol 32(1):30\u201344. https:\/\/doi.org\/10.1016\/j.tcb.2021.07.001","journal-title":"Trends Cell Biol"},{"issue":"8","key":"11716_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrm3629","volume":"14","author":"C Bertoli","year":"2013","unstructured":"Bertoli C, Skotheim JM, de Bruin RA (2013) Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 14(8):518\u2013528. https:\/\/doi.org\/10.1038\/nrm3629","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"11716_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","volume":"57","author":"A Shanabag","year":"2025","unstructured":"Shanabag A, Armand J, Son E, Yang HW (2025) Targeting CDK4\/6 in breast cancer. Exp Mol Med 57(2):312\u2013322. https:\/\/doi.org\/10.1038\/s12276-025-01395-3","journal-title":"Exp Mol Med"},{"issue":"7","key":"11716_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol 13(7):417\u2013430. https:\/\/doi.org\/10.1038\/nrclinonc.2016.26","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"11716_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC (2024) The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol 21(2):89\u2013105. https:\/\/doi.org\/10.1038\/s41571-023-00840-4","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"11716_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez M, Malumbres M (2020) Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37(4):514\u2013529. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.010","journal-title":"Cancer Cell"},{"issue":"11","key":"11716_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, DeCristo MJ, McAllister SS, Zhao JJ (2018) CDK4\/6 Inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol 28(11):911\u2013925. https:\/\/doi.org\/10.1016\/j.tcb.2018.07.002","journal-title":"Trends Cell Biol"},{"issue":"3","key":"11716_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A (2021) Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs 81(3):317\u2013331. https:\/\/doi.org\/10.1007\/s40265-020-01461-2","journal-title":"Drugs"},{"issue":"171","key":"11716_CR9","doi-asserted-by":"publisher","first-page":"230145","DOI":"10.1183\/16000617.0145-2023","volume":"33","author":"S Lv","year":"2024","unstructured":"Lv S, Yang J, Lin J, Huang X, Zhao H, Zhao C, Yang L (2024) CDK4\/6 inhibitors in lung cancer: current practice and future directions. Eur Respir Rev 33(171):230145. https:\/\/doi.org\/10.1183\/16000617.0145-2023","journal-title":"Eur Respir Rev"},{"issue":"4","key":"11716_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","volume":"50","author":"J Huang","year":"2022","unstructured":"Huang J, Zheng L, Sun Z, Li J (2022) CDK4\/6 inhibitor resistance mechanisms and treatment strategies (Review). Int J Mol Med 50(4):128. https:\/\/doi.org\/10.3892\/ijmm.2022.5184","journal-title":"Int J Mol Med"},{"key":"11716_CR11","doi-asserted-by":"publisher","first-page":"103848","DOI":"10.1016\/j.critrevonc.2022.103848","volume":"180","author":"C Fontanella","year":"2022","unstructured":"Fontanella C, Giorgi CA, Russo S, Angelini S, Nicolardi L, Giarratano T, Frezzini S, Pestrin M, Palleschi D, Bolzonello S, Parolin V, Haspinger ER, De Rossi C, Greco F, Gerratana L (2022) Optimizing CDK4\/6 inhibitors in advanced HR+\/HER2- breast cancer: a personalized approach. Crit Rev Oncol Hematol 180:103848. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103848","journal-title":"Crit Rev Oncol Hematol"},{"key":"11716_CR12","doi-asserted-by":"publisher","first-page":"108095","DOI":"10.1016\/j.bioorg.2024.108095","volume":"154","author":"M Shen","year":"2025","unstructured":"Shen M, Ma Z, Zhu J, Wen G, Jin H, An J, Tuo B, Liu X, Li T (2025) CDK4\/6 inhibitors in HR-positive breast cancer immunotherapy. Bioorg Chem 154:108095. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108095","journal-title":"Bioorg Chem"},{"issue":"4","key":"11716_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.fmre.2024.02.011","volume":"4","author":"H Wu","year":"2024","unstructured":"Wu H, Liu J, Zhang R, Lu Y, Cui G, Cui Z, Ding Y (2024) A review of deep learning methods for ligand based drug virtual screening. Fundam Res 4(4):715\u2013737. https:\/\/doi.org\/10.1016\/j.fmre.2024.02.011","journal-title":"Fundam Res"},{"issue":"10","key":"11716_CR14","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1039\/d5md00494b","volume":"16","author":"MS Elgawish","year":"2025","unstructured":"Elgawish MS, Almatary AM, Zaitone SA, Salem MSH (2025) Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects. RSC Med Chem 16(10):4698\u20134720. https:\/\/doi.org\/10.1039\/d5md00494b","journal-title":"RSC Med Chem"},{"issue":"D1","key":"11716_CR15","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","volume":"52","author":"B Zdrazil","year":"2024","unstructured":"Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizil\u00f6ren T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR (2024) The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res 52(D1):D1180\u2013D1192. https:\/\/doi.org\/10.1093\/nar\/gkad1004","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"11716_CR16","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1038\/s41596-023-00885-w","volume":"18","author":"VK Tran-Nguyen","year":"2023","unstructured":"Tran-Nguyen VK, Junaid M, Simeon S, Ballester PJ (2023) A practical guide to machine-learning scoring for structure-based virtual screening. Nat Protoc 18(11):3460\u20133511. https:\/\/doi.org\/10.1038\/s41596-023-00885-w","journal-title":"Nat Protoc"},{"issue":"10","key":"11716_CR17","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1021\/acs.molpharmaceut.4c00659","volume":"21","author":"F Miljkovi\u0107","year":"2024","unstructured":"Miljkovi\u0107 F, Bajorath J (2024) Kinase drug discovery: impact of open science and artificial intelligence. Mol Pharm 21(10):4849\u20134859. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00659","journal-title":"Mol Pharm"},{"issue":"12","key":"11716_CR18","doi-asserted-by":"publisher","first-page":"104518","DOI":"10.1016\/j.drudis.2025.104518","volume":"30","author":"J Delile","year":"2025","unstructured":"Delile J, Mukherjee S, Mueller J, Khalil I, Zhukov L, Meier C (2025) Foundation models in drug discovery: phenomenal growth today, transformative potential tomorrow? Drug Discov Today 30(12):104518. https:\/\/doi.org\/10.1016\/j.drudis.2025.104518","journal-title":"Drug Discov Today"},{"issue":"D1","key":"11716_CR19","doi-asserted-by":"publisher","first-page":"D609","DOI":"10.1093\/nar\/gkae1010","volume":"53","author":"UniProt","year":"2025","unstructured":"UniProt (2025) the Universal Protein Knowledgebase in 2025. Nucleic Acids Res 53(D1):D609\u2013D617. https:\/\/doi.org\/10.1093\/nar\/gkae1010","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"11716_CR20","doi-asserted-by":"publisher","first-page":"D488","DOI":"10.1093\/nar\/gkac1077","volume":"51","author":"SK Burley","year":"2023","unstructured":"Burley SK, Bhikadiya C, Bi C, Bittrich S, Chao H, Chen L, Craig PA, Crichlow GV, Dalenberg K, Duarte JM, Dutta S, Fayazi M, Feng Z, Flatt JW, Ganesan S, Ghosh S, Goodsell DS, Green RK, Guranovic V, Henry J, Hudson BP, Khokhriakov I, Lawson CL, Liang Y, Lowe R, Peisach E, Persikova I, Piehl DW, Rose Y, Sali A, Segura J, Sekharan M, Shao C, Vallat B, Voigt M, Webb B, Westbrook JD, Whetstone S, Young JY, Zalevsky A, Zardecki C (2023) RCSB Protein Data Bank (RCSB.org) : delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence\/machine learning. Nucleic Acids Res 51(D1):D488\u2013D508. https:\/\/doi.org\/10.1093\/nar\/gkac1077","journal-title":"Nucleic Acids Res"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11716-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:05:45Z","timestamp":1793858745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11716-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["11716"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11716-x","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}